⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMLX News
Amylyx Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
AMLX
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
businesswire.com
AMLX
Form 8-K
sec.gov
AMLX
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
AMLX
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
businesswire.com
AMLX
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
businesswire.com
AMLX
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
prnewswire.com
AMLX
INVESTOR ALERT AND NOTICE: Kaskela Law Firm Announces Investigation of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) and Encourages Long-Term Amylyx Investors with Losses to Contact the Firm
accessnewswire.com
AMLX
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
businesswire.com
AMLX
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
businesswire.com
AMLX